Callan JMB Amends Stock Purchase Agreement, Extends Maturity and Revises Dilutive Terms
CJMB sits 66% above its 52-week low of $1.082.
Summary
Callan JMB Inc. amended its stock purchase agreement, extending the maturity date but also revising terms that could lead to increased dilution and stock price pressure.
Key Events · Financing and Capital Events · CJMB
-
Purchase Agreement Amended
Callan JMB Inc. entered into Amendment No. 1 to its Common Stock Purchase Agreement with Hexstone Capital, LLC, originally dated July 24, 2025.
-
Maturity Date Extended
The maturity date of the agreement has been extended to April 1, 2027, providing the company with a longer period to access capital.
-
Revised Purchase Price
The regular purchase price for shares sold to Hexstone Capital, LLC is now 95% of the lowest daily trading price during the measurement period, or 75% if the stock is suspended or delisted.
-
Increased Leak-Out Provision
The investor's monthly resale limitation has been revised to the greater of $25,000 per trading day or 20.0% of the daily trading volume, potentially allowing for more rapid share sales.
Analysis · CJMB · Trade & Services
Callan JMB Inc. has amended its existing Common Stock Purchase Agreement with Hexstone Capital, LLC, extending the maturity date to April 1, 2027. While the extension provides additional financial runway, the revised terms introduce more aggressive dilutive potential. The purchase price is now set at 95% of the lowest daily trading price, and the investor's monthly resale limitation has been increased to the greater of $25,000 per trading day or 20% of daily trading volume. For a micro-cap company, these terms can lead to significant ongoing dilution and exert downward pressure on the stock price as the investor liquidates shares. Investors should monitor the volume of shares sold by Hexstone Capital.
At the time of this filing, CJMB was trading at $1.80 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $1.08 to $6.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.